Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Large Drop in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totaling 255,031 shares, a drop of 64.0% from the April 30th total of 708,414 shares. Based on an average daily volume of 1,289,720 shares, the short-interest ratio is currently 0.2 days. Approximately 3.3% of the shares of the stock are sold short.

Institutional Investors Weigh In On Cel-Sci

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Cel-Sci by 59.7% in the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after purchasing an additional 109,352 shares during the period. Bank of America Corp DE boosted its stake in Cel-Sci by 2,188.2% during the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after acquiring an additional 39,190 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock worth $115,000 after acquiring an additional 20,484 shares in the last quarter. Geode Capital Management LLC grew its holdings in Cel-Sci by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after purchasing an additional 18,432 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Cel-Sci during the fourth quarter valued at approximately $83,000. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Price Performance

Shares of CVM traded up $0.06 during midday trading on Friday, reaching $1.54. The stock had a trading volume of 188,823 shares, compared to its average volume of 916,515. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $13.07 million, a price-to-earnings ratio of -0.16 and a beta of 0.70. The company’s 50-day moving average is $2.85 and its 200 day moving average is $4.51. Cel-Sci has a 12-month low of $0.89 and a 12-month high of $13.48.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.